Denosumab for the treatment of therapy-induced bone loss in non-metastatic breast cancer
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- Referral date:
- 01 April 2009
- Topic area
- Cancer, Musculoskeletal
- Description:
-
Cancer reform strategy Batch 6
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
Project Team
- Communications manager:
- Laura Gibson
- Executive Lead:
- Gillian Leng
- Project manager:
- Jeremy Powell
- Technical Lead:
- Scott Goulden
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 4 January 2010 | The manufacturer of denosumab has indicated that they will not make a submission for this appraisal. We have therefore suspended the appraisal. |
| 2 August 2010 | Denosumab has not received a separate marketing authorisation for this indication. The Department of Health have therefore removed this appraisal from NICE’s work programme. |
For further information on our processes and methods, please see our CHTE processes and methods manual